Press Releases
GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease
Dr. Jeffrey Miller to Present Data on GT Biopharma Next Generation TriKE (OXS-C3550) at the Upcoming ASH Meeting in Atlanta, Ga
GT Biopharma, Inc. Announces Shawn M. Cross, 20-Year Healthcare Investment Banking Industry Veteran, as President and Chief Operating Officer
GT Biopharma Announces Approved FDA IND Transfer of Its First TriKE (OXS-3550)
GT Biopharma Begins Manufacturing of "Non-Opioid" Pain-Brake Drug to Compete in Multi-Billion Dollar Chronic Pain Market
GT Biopharma Announces Stock Sales Agreement with Holders of Converted Securities
GT Biopharma Announces Completion of First Four Patients in FDA Phase 2 Trial of Cancer Drug OXS-1550
GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo
Thomas N. Chase, MD, Joins GT Biopharma, Inc. as an Advisor to the Board
